Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979879

SCHEMBL1979879

SCHEMBL1979879

O=[N+]([O-])c1cc(F)c2c(c1)CCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.41
▸ ALDH1A1 P00352 7/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ HIF1A Q16665 2/20 0.36
▸ CYP19A1 P11511 1/20 0.35
▸ ADRA2A P08913 1/20 0.34
▸ PNMT P11086 1/20 0.34
▸ MAPT P10636 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TTR P02766 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10580640 0.81 ALDH1A1 (0.41) ALDH1A1KMT2AHIF1ACYP19A1MAPT
SCHEMBL8550097 0.80 GPR35 (0.43) PARP1ALDH1A1KMT2AHIF1ACYP19A1
SCHEMBL29814297 0.80 GPR35 (0.43) PARP1ALDH1A1KMT2AHIF1ACYP19A1
SCHEMBL7084146 0.80 MEN1 (0.46) PARP1ALDH1A1KMT2ACYP19A1ADRA2A
SCHEMBL8550301 0.80 GPR35 (0.41) PARP1ALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL8117804 0.80 ALDH1A1 (0.42) PARP1ALDH1A1KMT2ACYP19A1ADRA2A
SCHEMBL15427979 0.80 ALDH1A1 (0.48) PARP1ALDH1A1KMT2ACYP19A1ADRA2A
SCHEMBL7484667 0.80 ALDH1A1 (0.42) PARP1ALDH1A1KMT2ACYP19A1ADRA2A
SCHEMBL19775788 0.78 MAPT (0.43) ALDH1A1KMT2AHIF1ACYP19A1MAPT
SCHEMBL727921 0.76 PARP1 (0.44) PARP1ALDH1A1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 — — US disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 — — US disclosed
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 — — CN disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
EP-4278014-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed
WO-2022152822-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2022-07-21 — — WO disclosed
CN-104109165-A 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2014-10-22 — — CN disclosed
US-8227501-B2 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds FERRER INTERNACIONAL, S.A. (ES) 2012-07-24 — — US disclosed
US-8227501-B2 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds FERRER INTERNACIONAL, S.A. (ES) 2012-07-24 — — US disclosed
US-8227501-B2 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds FERRER INTERNACIONAL, S.A. (ES) 2012-07-24 — — US disclosed
EP-2350088-A1 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS Ferrer Internacional, S.A. (ES) 2011-08-03 — — EP disclosed
US-20110144178-A1 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS FERRER INTERNACIONAL, S.A. (ES) 2011-06-16 — — US disclosed
US-20110144178-A1 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS FERRER INTERNACIONAL, S.A. (ES) 2011-06-16 — — US disclosed
US-20110144178-A1 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS FERRER INTERNACIONAL, S.A. (ES) 2011-06-16 — — US disclosed
WO-2010012789-A1 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS FERRER INTERNACIONAL S. A. (ES) 2010-02-04 — — WO disclosed
WO-2010012789-A1 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS FERRER INTERNACIONAL S. A. (ES) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 PARP1 4554/4885ALDH1A1 1142/4885KMT2A 1951/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 PARP1 4554/4885ALDH1A1 1142/4885KMT2A 1951/4885
US-20110144178-A1 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS MTNR1A, MTNR1B, ADORA2A PARP1 1889/4885ALDH1A1 220/4885KMT2A 895/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 PARP1 4647/4885ALDH1A1 1370/4885KMT2A 1988/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 PARP1 4554/4885ALDH1A1 1142/4885KMT2A 1951/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 PARP1 225/4885ALDH1A1 4276/4885KMT2A 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.